STOCK TITAN

Know Labs, Inc. - KNW STOCK NEWS

Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.

Know Labs, Inc. (KNW) is a pioneering company in the medical diagnostics sector, dedicated to the development, marketing, and sales of cutting-edge technologies. The company specializes in utilizing electromagnetic energy to identify, authenticate, and analyze various substances and materials through its proprietary Bio-RFID and ChromaID technologies.

The Bio-RFID technology is revolutionizing the industry by enabling non-invasive glucose monitoring, providing a significant advancement for diabetes management. Similarly, the ChromaID technology uses structured light to capture unique spectral patterns known as ChromAIDs, which can be matched against databases to identify and detect markers invisible to the human eye. These technologies offer potential solutions that were previously only possible with large, lab-based tests.

Know Labs is currently focused on the development of a wearable device designed to measure blood glucose levels without the need for fingersticks or microneedles. This innovative product aims to improve the quality of life for individuals with diabetes by providing a painless and convenient method of monitoring blood sugar levels.

The company has recently achieved significant milestones in its research and development efforts, showcasing its commitment to pushing the boundaries of medical diagnostics. Know Labs is also actively engaged in forging strategic partnerships to enhance its technological capabilities and expand its market reach.

Financially, Know Labs continues to invest in research and development, ensuring it remains at the forefront of medical diagnostic innovation. The company's disruptive technologies hold the promise of making advanced diagnostics more accessible and affordable, thereby transforming the landscape of healthcare.

For the latest updates, news, and developments related to Know Labs, Inc., visit our news section or follow us on our social media channels.

Rhea-AI Summary

Know Labs (KNWN) has filed an appeal against NYSE American's decision to delist the company due to its stock price falling below $0.10. During the appeal process, trading of Know Labs stock on NYSE American will be suspended, and the company has transitioned to trading on the OTC Markets under the symbol 'KNWN' effective January 29, 2025.

The company, which specializes in radio frequency dielectric spectroscopy (RFDS), recently initiated a licensing program through Know Labs Technology Licensing (KTL) and continues to advance its proprietary technology. Their primary focus remains on developing non-invasive diagnostics, particularly blood glucose monitoring, which will require FDA clearance before market introduction.

CEO Ron Erickson emphasized that despite the NYSE situation, the company has successfully reduced overhead, received peer-reviewed recognition, and maintains optimism about near-term licensing opportunities and revenue generation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Know Labs (NYSE American: KNW) announced that NYSE Regulation is initiating delisting proceedings due to the company's bid price falling under $.10, according to Section 1003(f)(v) of the NYSE American Company Guide. The company's stock will be suspended from NYSE American trading while Know Labs works on compliance measures and appeals the delisting determination.

Effective January 29, 2025, the company's stock will trade on the OTC Markets under the symbol 'KNWN'. CEO Ron Erickson emphasized that this development comes at a time when the company has initiated a licensing program, received peer-reviewed recognition, reduced overhead, and continued advancing its proprietary radio frequency dielectric spectroscopy (RFDS) technology. The company maintains its focus on developing non-invasive diagnostics, particularly blood glucose monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Know Labs (NYSE: KNW) has announced the formation of Know Labs Technology Licensing (KTL), a new business unit dedicated to licensing its radio frequency dielectric spectroscopy (RFDS) technology. Modeled after Qualcomm Technology Licensing, KTL aims to expand the application of RFDS beyond medical diagnostics into various industries including industrial processes, consumer electronics, automotive, and IoT networks.

The initiative emerged following significant third-party interest after the company's Skunkworks announcement in May 2024. KTL will provide Software Development Kits and RFDS test automation products to licensing partners. An early example includes the development of a 'smart steering wheel' for automotive safety applications.

While Know Labs maintains its focus on non-invasive medical diagnostics, particularly blood glucose monitoring, KTL will enable external partners to integrate RFDS technology across different sectors, potentially creating new revenue streams through licensing agreements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
none
Rhea-AI Summary

Know Labs (NYSE: KNW) has announced a registered direct offering priced at-the-market, raising $300,000 in gross proceeds before deducting fees and expenses. The offering consists of units, each comprising one share of stock and one warrant at $0.24 per unit. The warrants are exercisable at $0.24 and will expire after five years, featuring a cashless exercise option under certain circumstances.

The offering is being conducted under the company's effective shelf registration statement on Form S-3, which was filed with the SEC on December 22, 2023, and declared effective on January 11, 2024. A prospectus supplement dated December 13, 2024, has been filed to complement the base prospectus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.25%
Tags
-
Rhea-AI Summary

Know Labs (NYSE American: KNW) announced that NYSE American has accepted its compliance plan on December 10, 2024. The company has been granted until March 27, 2026 to regain compliance with the exchange's listing standards under Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide. During this period, KNW will undergo periodic reviews to assess progress with the plan's initiatives. The company's shares will continue trading on NYSE American, subject to meeting other listing requirements. If KNW fails to regain compliance by the deadline or show sufficient progress, NYSE American may initiate delisting proceedings. This development doesn't affect KNW's business operations or SEC reporting obligations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.16%
Tags
none
-
Rhea-AI Summary

Know Labs (NYSE American: KNW) released its FY2024 10-K annual report, addressing shareholder concerns about its going concern audit opinion. The company reported a $16 million net loss, including $5 million in non-cash charges. Key achievements include: development of 2nd generation KnowU™ CGM, completion of companion mobile app, filing of 68 new patents (total 332 active patents), and clinical studies showing 93% accuracy in glycemic level determination. The company reduced monthly cash burn by 42% to $700,000 and initiated strategic projects including a Smart Steering Wheel initiative. Management expressed confidence in accessing capital through their effective S-3 shelf offering to continue operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
none
Rhea-AI Summary

Know Labs (NYSE American: KNW) announced that its audited financial statements for the fiscal year ended September 30, 2024, received an audit opinion containing a going concern explanation from its independent registered public accounting firm. This disclosure, previously included in the company's Annual Report on Form 10-K filed on November 14, 2024, raises questions about the company's ability to continue operations. The announcement complies with NYSE American Company Guide Section 610(b) requirements and does not represent any changes to the company's financial statements or Annual Report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
none
-
Rhea-AI Summary

Know Labs (NYSE: KNW) reported its FY2024 financial results, showing a net loss of $16.58 million, an 8.4% increase from FY2023's loss of $15.29 million. The company's EPS loss improved to $0.20 from $0.41 in FY2023. R&D expenses decreased 21% to $6.11 million, while SG&A expenses increased to $9.11 million. Cash position declined to $3.11 million from $8.02 million year-over-year. The company expects its current cash to sustain operations through February 28, 2025, and plans to raise additional funds through equity, preferred stock, and convertible debentures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
-
Rhea-AI Summary

Know Labs, Inc. (NYSE American: KNW), a developer of non-invasive diagnostics technology, has announced two key additions to its executive leadership team. John Cronin joins as Interim Chief Technology Officer, bringing extensive experience in intellectual property strategy and patent development. Dominic Klyve, Ph.D., becomes Chief Science Officer, tasked with leading the research and development team in building the first non-invasive glucose monitor.

These appointments aim to accelerate platform development and secure multiple strategic partnerships. Cronin, previously a board member and strategic advisor, will oversee product development and technology strategy. Klyve, a former lead data scientist at Know Labs, brings significant research experience and has authored several studies for the company.

The expanded leadership team is expected to drive technology development and assist in bringing Know Labs' platform to market through strategic relationships with global leaders in med tech, pharma, and consumer markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.28%
Tags
none
Rhea-AI Summary

Know Labs (NYSE: KNW) has engaged The Stanbridge Group to establish a strategic partnership with an automotive OEM to integrate its non-invasive sensor technology into steering wheels. Initial lab tests show the sensor can detect blood alcohol levels non-invasively, potentially preventing impaired driving. This innovation emerged during the development of their glucose monitoring tech, leading to a patent filing in 2022, published in 2024 (US 2024/0050007 A1). The 2021 Infrastructure Investment and Jobs Act mandates passive alcohol detection systems in new vehicles by 2026, aligning with Know Labs' technology. CEO Ron Erickson highlighted the broad applications of their technology, including driver health and wellness. In 2022, drunk driving caused 13,524 deaths in the US, prompting NHTSA to propose rules for impaired driving prevention tech. Rick Stanbridge of The Stanbridge Group emphasized the sensor's potential to address manufacturers' and NHTSA's concerns. Further details are available at www.knowlabs.co.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none

FAQ

What is the current stock price of Know Labs (KNW)?

The current stock price of Know Labs (KNW) is $0.0856 as of February 7, 2025.

What is the market cap of Know Labs (KNW)?

The market cap of Know Labs (KNW) is approximately 9.5M.

What does Know Labs, Inc. specialize in?

Know Labs, Inc. specializes in the development, marketing, and sales of technologies that use electromagnetic energy to identify and authenticate substances and materials.

What is Bio-RFID technology?

Bio-RFID technology is a non-invasive method developed by Know Labs to measure blood glucose levels without fingersticks or microneedles.

What is ChromaID technology?

ChromaID technology uses structured light to capture unique spectral patterns, known as ChromAIDs, which can identify and detect markers invisible to the human eye.

What is the latest product being developed by Know Labs?

Know Labs is currently developing a wearable device that measures blood glucose levels non-invasively.

What are ChromAIDs?

ChromAIDs are unique spectral patterns captured by ChromaID technology, used to identify and detect various markers.

How does Know Labs' technology differ from traditional diagnostic methods?

Know Labs' technologies offer non-invasive, portable, and cost-effective diagnostic solutions that were traditionally only possible with large, lab-based equipment.

What are the recent achievements of Know Labs?

Know Labs has achieved significant milestones in research and development, advancing its Bio-RFID and ChromaID technologies and working on a non-invasive glucose monitoring device.

How does Know Labs contribute to diabetes management?

Know Labs is developing a wearable device for non-invasive glucose monitoring, which aims to provide a painless and convenient method for individuals to manage their blood sugar levels.

Who can benefit from Know Labs' technologies?

Individuals with diabetes, medical professionals, and various industries requiring substance identification and authentication can benefit from Know Labs' innovative technologies.

Where can I find the latest news about Know Labs, Inc.?

You can find the latest updates and news about Know Labs, Inc. on their news section on their website or follow them on social media channels.
Know Labs, Inc.

OTC:KNW

KNW Rankings

KNW Stock Data

9.52M
88.76M
26.05%
4.83%
1.2%
Scientific & Technical Instruments
Measuring & Controlling Devices, Nec
Link
United States
SEATTLE